Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
NCT ID: NCT05934864
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2023-07-13
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
NCT05907447
Cohort of Peripheral T Cell Lymphoma
NCT02364466
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
NCT02788916
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gene mutation profile of PTCL
84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
84-gene penal
84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
84-gene penal
84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with PTCL by histopathology from January 2023 to June 2023 and NGS detection can be performed if there is tumor tissue.
* Informed consented
* Age ≥ 18 years
Exclusion Criteria
* Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease
* Not able to comply to the protocol for mental or other unknown reasons
* Patients with mentally disorders or other reasons unable to fully comply with the study protocol
* Pregnant or lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Shandong Provincial Hospital
OTHER_GOV
RenJi Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhao Weili
Deputy Director of Hospital, Shanghai Rui Jin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, , China
Henan Cancer Hospital
Henan, , China
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, , China
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
Shandong, , China
Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, , China
Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Sichuan, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shenmiao Yang
Role: primary
Keshu Zhou
Role: primary
Jingyan Xu
Role: primary
Xin Wang
Role: primary
Ting Niu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RJ-PTCL-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.